Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial

Aims To evaluate the efficacy and safety of a novel sodium‐glucose cotransporter 2 inhibitor, enavogliflozin 0.3 mg monotherapy, in Korean people with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise. Materials and Methods This study was a randomized, double‐blind, plac...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2023-07, Vol.25 (7), p.1865-1873
Hauptverfasser:	Kwak, Soo Heon, Han, Kyung Ah, Kim, Kyung‐Soo, Yu, Jae Myung, Kim, EunSook, Won, Jong Chul, Kang, Jun Goo, Chung, Choon Hee, Oh, Seungjoon, Choi, Sung Hee, Won, Kyu Chang, Kim, Sin Gon, Cho, Seung Ah, Cho, Bo Young, Park, Kyong Soo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Blood Glucose Blood pressure Body Weight Cholesterol Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 Diet Double-Blind Method Double-blind studies Fasting Glucose Glycated Hemoglobin Hemoglobin Homeostasis Humans Hypoglycemic Agents - adverse effects Insulin resistance Lipids Placebos Republic of Korea - epidemiology Sodium-glucose cotransporter Sodium-Glucose Transporter 2 Inhibitors - adverse effects Statistical analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!